Ad
related to: monoclonal antibodies for covid treatment
Search results
Does COVID-19 Persist?
MedPage Today· 23 hours agoWith 17 million adults reporting long COVID symptoms like brain fog and fatigue, the idea of viral persistence has gained traction. "At the beginning of the pandemic, we never ...
Mirikizumab Shows Promise for Moderate to Severe Crohn's
Medscape· 23 hours agoAlready approved for ulcerative colitis, the monoclonal antibody mirikizumab met study endpoints for...
Sanofi to make €1bn biomanufacturing investment in France
Pharmaceutical Technology via Yahoo Finance· 7 days agoSanofi plans to invest €1bn in Vitry-sur-Seine to construct a new unit in a bid to double the ...
5 Things to Know: COVID-19 Vaccines for Immunocompromised People
Medscape· 5 days agoCDC experts share what clinicians should know about COVID-19 prevention in immunocompromised...
Press Release: Dupixent® late-breaking data from NOTUS confirmatory phase 3 COPD study presented at...
Benzinga· 10 hours agoDupixent® late-breaking data from NOTUS confirmatory phase 3 COPD study presented at ATS and published in NEJM NOTUS results confirm landmark data from the phase 3 BOREAS study and show Dupixent significantly
HaemaLogiX welcomes former Australian Federal Minister for Health Professor the Hon Greg Hunt to the...
WKRN Nashville· 18 hours agoThis appointment marks the first corporate directorship that Prof Hunt has accepted since completing his period as Minister for Health. As the Federal Minister for Health from 2017 to 2022, ...
Small Business - The Andalusia Star-News | The Andalusia Star-News
The Andalusia Star-News· 2 days agoThe primary results showed that treatment with Tezspire led to a 17% numerical reduction in the annual rate of moderate or severe COPD exacerbations compared to placebo at ...
TREMFYA® (guselkumab) QUASAR Maintenance Study in UC met its primary endpoint and all major...
FOX 23 News Albany· 16 hours agoWASHINGTON, May 20, 2024 /PRNewswire/ -- Johnson & Johnson today announced the first data from the Phase 3 QUASAR Maintenance Study (Abstract #759) that showed 50.0 percent (p<0.001) of patients ...
Earnings call: Dyadic International Eyes Growth in Health and Proteins
Investing.com· 3 days agoDyadic International has made notable progress in the human health sector, particularly with its ...
Critics Say FDA's Use of Surrogate Markers Falling Short
Medscape· 4 days agoAs the FDA's use of surrogate endpoints in the drug approval process is increasing, researchers are...
